News

Panion acquires access to dog study

Panion has made an agreement with Copenhagen University about transfer and use of technical data from a study in dogs. 

The study is conducted by well-reputed researchers and is very relevant for Panion's development of our gene therapy product for dogs with epilepsy. The study is not yet published by the researchers, but Panion may use the data in the contact with FDA and other authorities to speed up the development process from the day the agreement is signed.

"We are very pleased with the agreement, and we expect that this will ease our way to the next trial for our innovative product and to the market" says Anja Holm, CEO of Panion Animal Health.

AUGUST 14 2017

For further information, please contact:
Anja E. H. Holm, VD | + 45-22 94 66 00 
anja.holm@panion-animalhealth.com

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on August 14 2017.

In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet linkedin.com/company/panion-animalhealth AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGe- ne's shareholders with the aim of listing the company. The company, which has been twitter.com/panionanihealth renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a panion-animalhealth.com/newsletter treatment for canine epilepsy. Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

2017-08-21

Period April-June

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -1 269 (0)
  • Earnings per share: SEK -0,10 (-).
  • Liquidity at the end of the period: kSEK 796 (582).

Period January-June

  • Net sales: kSEK 0 (0). 
  • Operating profit: kSEK -2 536 (-). 
  • Earnings per share: SEK -0,21 (-). 
  • Liquidity at the end of the period: kSEK 796 (582).
2017-08-14

Panion has made an agreement with Copenhagen University about transfer and use of technical data from a study in dogs. 

2017-07-14

After raising new capital, veterinary medicine company Panion Animal Health AB is now ready to ramp
up development of its treatment method for canine epilepsy. At the same time, discussions are under
way for a licensing deal that could give Panion access to a new major market.

2017-07-03

Panion Animal Health AB (publ) ("Panion") has received approval for admission to trading of its shares on AktieTorget. The listing of Panion on AktieTorget facilitates distribution of CombiGene's shares in Panion to CombiGene's shareholders. The first day of trading in Panion's share on AktieTorget is Thursday, 6 July 2017.

1
2
3
4
5

Subscribe

Press releases and reports via E-mail.